Use of immune checkpoint inhibitors in patients with lung cancer and multiple sclerosis

Lung, Respiratory and Thoracic Cancer

Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy

Eur J Cancer

Saalfeld FC, Möller J, Christopoulos P, Wenzel C, Rasokat A, Wang XA, Vathiotis I, König D, Illini O, Grohé C, Wiesweg M, Wesseler C, Schubart C, Pelusi N, Rohde G, Overbeck TR, Kirfel J, Alt J, Kauffmann-Guerrero D, Griesinger F, Kulhavy J, Allgäuer M, Klimova A, Schütz M, Aust DE, Hochmair MJ, Rothschild SI, Syrigos KN, Veluswamy R, Michels S, Stenzinger A, Jöhrens K, Wermke M

doi: 10.1016/j.ejca.2024.115065

Further Publications

Real-world response assessment of immune checkpoint inhibition: comparing iRECIST and RECIST 1.1 in melanoma and non-small cell lung cancer patients

Eur Radiol

Nelles C, Gräf M, Bernard P, Persigehl T, Große Hokamp N, Zopfs D, Maintz D, Kreuzberg N, Wolf J, Bröckelmann PJ, Lennartz S

doi: 10.1007/s00330-024-11060-4

Lung, Respiratory and Thoracic Cancer

Efficacy and safety of immune checkpoint inhibition combined with concurrent chemoradiotherapy in patients with stage III unresectable non-small cell lung cancer: A systematic review and meta-analysis

Eur J Cancer

Acker F, Reck M, Martin D, Rieken S, Heinzen S, Rost M, Aguinarte L, Schulte H, Serve H, Oellerich T, Sebastian M, Althoff FC

doi: 10.1016/j.ejca.2025.115266

Further Publications

Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors

Eur J Cancer

Ruf T, Kramer R, Forschner A, Leiter U, Meier F, Reinhardt L, Dücker P, Ertl C, Tomsitz D, Tietze JK, Gutzmer R, Dabrowski E, Zimmer L, Gesierich A, Zierold S, French LE, Eigentler T, Amaral T, Heinzerling L

doi: 10.1016/j.ejca.2024.114028

Genitourinary Cancer

The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis

Cancer Treat Rev

Zhang Y, Chen J, Liu H, Dai J, Zhao J, Zhu S, Zhang X, Liang J, Hu X, Zhao J, Liu Z, Shen P, Sun G, Zeng H

doi: 10.1016/j.ctrv.2024.102787

Lung, Respiratory and Thoracic Cancer

Validation of the Lung Immune Prognostic Index in patients with untreated advanced non-small cell lung cancer: Post hoc analysis of the IMpower 130, 131 and 150 trials

Lung Cancer

Auclin E, Roulleaux Dugage M, Gorria T, Vauchier C, Thibault C, Laguna JC, Lupinacci L, Crous C, Naigeon M, Oudard S, Besse B, Mezquita L

doi: 10.1016/j.lungcan.2024.108039

Lung, Respiratory and Thoracic Cancer

Brain metastases and mortality in patients with ALK + metastatic non-small cell lung cancer treated with second-generation ALK tyrosine kinase inhibitors as first-line targeted therapies: An observational cohort study

Lung Cancer

Uprety D, Abrahami D, Marcum ZA, Li B, Sang A, Davis M, Rifi N, Kelton JM, Ramaswamy K, Sanghvi P, Bazhenova L

doi: 10.1016/j.lungcan.2025.108436

Further Publications

A systematic review and meta-analysis of observational studies and uncontrolled trials reporting on the use of checkpoint blockers in patients with cancer and pre-existing autoimmune disease

Eur J Cancer

Lopez-Olivo MA, Kachira JJ, Abdel-Wahab N, Pundole X, Aldrich JD, Carey P, Khan M, Geng Y, Pratt G, Suarez-Almazor ME

doi: 10.1016/j.ejca.2024.114148

Lung, Respiratory and Thoracic Cancer

Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1-49 %): TOPGAN2023-01

Eur J Cancer

Tanaka H, Makiguchi T, Tozuka T, Kawashima Y, Oba T, Tsugitomi R, Koyama J, Tambo Y, Ogusu S, Saiki M, Gyotoku H, Hasegawa T, Miyauchi E, Sonoda T, Saito R, Nakatomi K, Sakatani T, Kudo K, Tsuchiya-Kawano Y, Nishio M

doi: 10.1016/j.ejca.2024.115117

Related content

Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy

Real-world response assessment of immune checkpoint inhibition: comparing iRECIST and RECIST 1.1 in melanoma and non-small cell lung cancer patients

Efficacy and safety of immune checkpoint inhibition combined with concurrent chemoradiotherapy in patients with stage III unresectable non-small cell lung cancer: A systematic review and meta-analysis

Second-line therapies for steroid-refractory immune-related adverse events in patients treated with immune checkpoint inhibitors

The incidence of immune-related adverse events (irAEs) and their association with clinical outcomes in advanced renal cell carcinoma and urothelial carcinoma patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis

Validation of the Lung Immune Prognostic Index in patients with untreated advanced non-small cell lung cancer: Post hoc analysis of the IMpower 130, 131 and 150 trials

Brain metastases and mortality in patients with ALK + metastatic non-small cell lung cancer treated with second-generation ALK tyrosine kinase inhibitors as first-line targeted therapies: An observational cohort study

A systematic review and meta-analysis of observational studies and uncontrolled trials reporting on the use of checkpoint blockers in patients with cancer and pre-existing autoimmune disease

Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1-49 %): TOPGAN2023-01